

Product datasheet for SR413476

Serpina5 Mouse siRNA Oligo Duplex (Locus ID 268591)

Product data:

| Product Type: | siRNA Oligo Duplexes |
|---------------------|---|
| Purity: | HPLC purified |
| Quality Control: | Tested by ESI-MS |
| Sequences: | Available with shipment |
| Stability: | One year from date of shipment when stored at -20°C. |
| # of transfections: | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
| Note: | Single siRNA duplex (10nmol) can be ordered. |
| RefSeq: | <u>NM 172953</u> |
| UniProt ID: | <u>P70458</u> |
| Synonyms: | 4933415L04; PAI-3; Pci |
| Components: | Serpina5 (Mouse) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 268591) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

GRIGENE Serpina5 Mouse siRNA Oligo Duplex (Locus ID 268591) – SR413476

Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates Summary: serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinarytype plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid (By similarity).[UniProtKB/Swiss-Prot Function]

PerformanceOriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit willGuaranteed:provide at least 70% or more knockdown of the target mRNA when used at 10 nM
concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control
duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT
positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US